Skip to content

Effect of subclinical dose of esketamine on depression and pain after cesarean section

Effect of subclinical dose of esketamine on postpartum depression and pain - ESEDPACS

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080884
Enrollment
Unknown
Registered
2024-02-15
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression and pain after cesarean section

Interventions

Esketamine Group (S Group):After delivery, 0.25mg/kg esketamine was given after umbilical cord blood was ligation
Control Group(C Group):After the birth of the newborn, the umbilical cord blood was ligation and the same dose of normal saline was given about 5ml

Sponsors

Yongchuan Hospital affiliated to Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) Full-term pregnant women aged 18-40 years, (2) No history of depression before or during pregnancy, no family history of depression, (3) Body mass index (BMI) =30Kg/m2, (4) Willing to cooperate and sign consent form, and (5) ASA grade I-II.

Exclusion criteria

Exclusion criteria: 1 Pregnant women with a history of depression or depressive symptoms before birth; 2 Preterm birth or less than a month of maternity; 3 Body mass index >30kg/m2; 4. Pregnant women with serious obstetric diseases or with vital organ diseases before delivery; 5. Pregnant women or pregnant women with thyroid insufficiency or severe anemia; 6 Pregnant women allergic to esketamine; 7. Mothers who are unwilling to cooperate and refuse to sign the consent form; 8 Women who had been included in other studies, 9 Women with multiple pregnancies.

Design outcomes

Primary

MeasureTime frame
Postnatal depression;Postoperative Pain;

Secondary

MeasureTime frame
The dosage of postoperative analgesics in each group;The occurrence of related complications;

Countries

China

Contacts

Public ContactXiangqian Wan

Yongchuan Hospital affiliated to Chongqing Medical University

286624122@qq.com+86 183 8101 5045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026